Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 117

Sort by

Sort Order Select

Journal Articles

Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee

Francesco Onida, Nico Gagelmann, Yves Chalandon, Guido Kobbe, Marie Robin, Argiris Symeonidis, Theo de Witte, Raphael Itzykson, Madlen Jentzsch, Uwe Platzbecker, Valeria Santini, Guillermo Sanz, Christof Scheid, Eric Solary, Peter Valent, Raffaela Greco, Isabel Sanchez-Ortega, Ibrahim Yakoub-Agha, Lisa Pleyer

Blood (2024) 143 (22): 2227–2244.

https://doi.org/10.1182/blood.2023023476

Published: 2024

Includes: Supplemental data

Journal Articles

Hyperleukocytosis Increases the Risk of Early Relapses Independently of Genetics in AML

Raphaël Liévin, Nicolas Duployez, Loïc Vasseur, Juliette Lambert, Mael Heiblig, Mathilde Hunault, Claude Gardin, Stephane De Botton, Elise Fournier, Cecile Pautas, Christine Terré, Eric Delabesse, Norbert Ifrah, Arnaud Pigneux, Celli-Lebras Karine, Christian Recher, Claude Preudhomme, Herve Dombret, Raphael Itzykson

Blood (2023) 142 (Supplement 1): 4322.

https://doi.org/10.1182/blood-2023-173614

Published: 2023

Journal Articles

The Splicing-Associated Network PAK1-Clk-SRRM1 Is a Critical Vulnerability to Overcome Chemoresistance in Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 409.

https://doi.org/10.1182/blood-2023-186264

Published: 2023

Journal Articles

Prognostic Value and Functional Consequences of Calcium Signalling in Acute Myeloid Leukaemia

Stefan Djordjevic, Delphine Lebon, Raphael Itzykson, Hakim Ouled-Haddou, Guillaume Jedraszak, Juliette Harbonnier, Louison Collet, Etienne Paubelle, Nicolas Duployez, Jean Pierre Marolleau, Loïc Garçon, Thomas Boyer

Blood (2023) 142 (Supplement 1): 5678.

https://doi.org/10.1182/blood-2023-179276

Published: 2023

Journal Articles

Clonal Dynamics of FLT3 -ITD Positive Acute Myeloid Leukemia Patients with Relapsed/Refractory Disease Following Intensive Chemotherapy +/- Midostaurin

Romane Joudinaud, Augustin Boudry, Laurène Fenwarth, Sandrine Geffroy, Mikaël Salson, Herve Dombret, Céline Berthon, Arnaud Pigneux, Delphine Lebon, Lamya Haddaoui, Raphael Itzykson, Christian Recher, Audrey Bidet, Eric Delabesse, Mathilde Hunault, Claude Preudhomme, Nicolas Duployez, Pierre-Yves Dumas

Blood (2023) 142 (Supplement 1): 976.

https://doi.org/10.1182/blood-2023-182018

Published: 2023

Journal Articles

Mutational Profile and Dynamics of PPM1D -Mutant Clones in the Spectrum of Myeloid Disorders

Blood (2023) 142 (Supplement 1): 4064.

https://doi.org/10.1182/blood-2023-189428

Published: 2023

Journal Articles

Molecular Classification of Chronic Myelomonocytic Leukemia: Results of the Analysis of an International Cohort of 2,471 Patients

Luca Lanino, Anthony M. Hunter, Claudia Sala, Daniele Dall'Olio, Lorenzo Dall'Olio, Lisa Pleyer, Blanca Xicoy, Manja Meggendorfer, Elisabetta Sauta, Erica Travaglino, Marie Robin, Laura Palomo, David Quintela, Andres Jerez, Elena Cornejo, Paloma Garcia Martin, Marina Díaz-Beyá, Alejandro Avendaño Pita, Veronica Roldan, Dolly Viviana Fiallo Suarez, Estefania Cerezo Velasco, Marisa Calabuig, Giulia Rivoli, Massimo Bernardi, Francesco Onida, Lorenza Maria Borin, Francesco Passamonti, Alessia Campagna, Marta Ubezio, Antonio Russo, Gabriele Todisco, Giulia Maggioni, Cristina Astrid Tentori, Filippo Viviani, Alessandro Buizza, Gianluca Asti, Matteo Zampini, Armando Santoro, Wolfgang Kern, Uwe Platzbecker, Francesc Sole, Maria Diez-Campelo, Angela Consagra, Najla H Al Ali, David A Sallman, Pierre Fenaux, Raphael Itzykson, Michaela Fontenay, Amer M. Zeidan, Rami S. Komrokji, Valeria Santini, Torsten Haferlach, Ulrich Germing, Saverio D'Amico, Gastone Castellani, Eric Solary, Eric Padron, Matteo Giovanni Della Porta

Blood (2023) 142 (Supplement 1): 3244.

https://doi.org/10.1182/blood-2023-184536

Published: 2023

Journal Articles

Revisiting coexisting chromosomal abnormalities in NPM1 -mutated AML in light of the revised ELN 2022 classification

Linus Angenendt, Christoph Röllig, Pau Montesinos, Farhad Ravandi, Gunnar Juliusson, Christian Récher, Raphaël Itzykson, Zdeněk Ráčil, Andrew H. Wei, Christoph Schliemann

Blood (2023) 141 (4): 433–435.

https://doi.org/10.1182/blood.2022018582

Published: 2023

Journal Articles

Azithromycin promotes relapse by disrupting immune and metabolic networks after allogeneic stem cell transplantation

Blood (2022) 140 (23): 2500–2513.

https://doi.org/10.1182/blood.2022016926

Published: 2022

Includes: Supplemental data

Journal Articles

Persistence of Mutations in Complete Remission Including DNMT3A , TET2 and ASXL1 Mutations Is Associated with Worse Prognosis in Patients with Acute Myeloid Leukemia Treated in ALFA 0702 Study

Pierre Hirsch, Jérôme Lambert, Maxime Bucci, Caroline Deswarte, Juliette Lambert, Laurène Fenwarth, Herve Dombret, Nicolas Duployez, Claude Preudhomme, Raphael Itzykson, Francois Delhommeau

Blood (2022) 140 (Supplement 1): 549–550.

https://doi.org/10.1182/blood-2022-166713

Published: 2022

Journal Articles

AML MRD By Multiparameter Flow Cytometry Using Laip/Dfn and LSC: Methodological Aspects in a Multicentric Study of the French-Flow MRD AML ALFA Network

Blood (2022) 140 (Supplement 1): 6279–6281.

https://doi.org/10.1182/blood-2022-169696

Published: 2022

Journal Articles

Characteristics of Germline CHEK2 Mutated Patients in a Large Cohort of 2322 Myeloid Malignancies

Lucie Freiman, Lise Larcher, Giulia Tueur, Nadia Vasquez, Mélanie Da Costa, Emmanuel Raffoux, Lionel Ades, Pierre Fenaux, Jean Soulier, Emmanuelle Clappier, Raphael Itzykson

Blood (2022) 140 (Supplement 1): 4082–4083.

https://doi.org/10.1182/blood-2022-158799

Published: 2022

Journal Articles

Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry: A Report on 197 Cases

Blood (2022) 140 (Supplement 1): 9802–9803.

https://doi.org/10.1182/blood-2022-167716

Published: 2022

Journal Articles

LSC17 Score Is Complementary with Minimal Residual Disease to Stratify NPM1 -Mutated Acute Myeloid Leukemia: An ALFA Study

Blood (2022) 140 (Supplement 1): 6303–6305.

https://doi.org/10.1182/blood-2022-163348

Published: 2022

Journal Articles

Prognostic Impact of Monoallelic Versus Biallelic TP53 Alterations in Intensively-Treated Adults AML Patients: A Retrospective Study from the ALFA Group

Laurène Fenwarth, Loïc Vasseur, Nicolas Duployez, Claude Gardin, Christine Terré, Juliette Lambert, Stéphane de Botton, Karine Celli-Lebras, Pascal Turlure, Thomas Cluzeau, Thorsten Braun, Xavier Thomas, Christian Recher, Sylvain Chantepie, Cécile Pautas, Hervé Dombret, Claude Preudhomme, Raphael Itzykson

Blood (2022) 140 (Supplement 1): 737–738.

https://doi.org/10.1182/blood-2022-163044

Published: 2022

Journal Articles

Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysis

Blood (2022) 140 (12): 1408–1418.

https://doi.org/10.1182/blood.2021015173

Published: 2022

Includes: Supplemental data

Journal Articles

Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study

Blood (2022) 140 (7): 756–768.

https://doi.org/10.1182/blood.2021015328

Published: 2022

Includes: Supplemental data

Journal Articles

Ivosidenib Monotherapy Is Effective in Patients with IDH1 Mutated Myelodysplastic Syndrome (MDS): The Idiome Phase 2 Study By the GFM Group

Blood (2021) 138 (Supplement 1): 62.

https://doi.org/10.1182/blood-2021-146932

Published: 2021

Journal Articles

Enasidenib (ENA) Is Effective in Patients with IDH2 Mutated Myelodysplastic Syndrome (MDS) : The Ideal Phase 2 Study By the GFM Group

Blood (2021) 138 (Supplement 1): 63.

https://doi.org/10.1182/blood-2021-147898

Published: 2021

Journal Articles

Prognostic Significance of DDX41 Germline Mutations in Intensively Treated AML Patients: An ALFA-Filo Study

Nicolas Duployez, Matthieu Duchmann, Laetitia Largeaud, Juliette Lambert, Audrey Bidet, Emmanuelle Clappier, Xavier Thomas, Stephane de Botton, Claude Gardin, Christian Recher, Arnaud Pigneux, Raphael Itzykson, Claude Preudhomme, Hervé Dombret, Eric Delabesse, Marie Sebert

Blood (2021) 138 (Supplement 1): 612.

https://doi.org/10.1182/blood-2021-148465

Published: 2021

NARROW

Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee

Hyperleukocytosis Increases the Risk of Early Relapses Independently of Genetics in AML

The Splicing-Associated Network PAK1-Clk-SRRM1 Is a Critical Vulnerability to Overcome Chemoresistance in Acute Myeloid Leukemia

Prognostic Value and Functional Consequences of Calcium Signalling in Acute Myeloid Leukaemia

Clonal Dynamics of FLT3 -ITD Positive Acute Myeloid Leukemia Patients with Relapsed/Refractory Disease Following Intensive Chemotherapy +/- Midostaurin

Mutational Profile and Dynamics of PPM1D -Mutant Clones in the Spectrum of Myeloid Disorders

Molecular Classification of Chronic Myelomonocytic Leukemia: Results of the Analysis of an International Cohort of 2,471 Patients

Revisiting coexisting chromosomal abnormalities in NPM1 -mutated AML in light of the revised ELN 2022 classification

Azithromycin promotes relapse by disrupting immune and metabolic networks after allogeneic stem cell transplantation

Persistence of Mutations in Complete Remission Including DNMT3A , TET2 and ASXL1 Mutations Is Associated with Worse Prognosis in Patients with Acute Myeloid Leukemia Treated in ALFA 0702 Study

AML MRD By Multiparameter Flow Cytometry Using Laip/Dfn and LSC: Methodological Aspects in a Multicentric Study of the French-Flow MRD AML ALFA Network

Characteristics of Germline CHEK2 Mutated Patients in a Large Cohort of 2322 Myeloid Malignancies

Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry: A Report on 197 Cases

LSC17 Score Is Complementary with Minimal Residual Disease to Stratify NPM1 -Mutated Acute Myeloid Leukemia: An ALFA Study

Prognostic Impact of Monoallelic Versus Biallelic TP53 Alterations in Intensively-Treated Adults AML Patients: A Retrospective Study from the ALFA Group

Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysis

Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study

Ivosidenib Monotherapy Is Effective in Patients with IDH1 Mutated Myelodysplastic Syndrome (MDS): The Idiome Phase 2 Study By the GFM Group

Enasidenib (ENA) Is Effective in Patients with IDH2 Mutated Myelodysplastic Syndrome (MDS) : The Ideal Phase 2 Study By the GFM Group

Prognostic Significance of DDX41 Germline Mutations in Intensively Treated AML Patients: An ALFA-Filo Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only